Le Lézard
Classified in: Health
Subject: FDA

IntraFuse Receives FDA 510(k) Clearance for FlexThreadtm Fibula Pin System

LOGAN, Utah, Nov. 1, 2017 /PRNewswire/ -- IntraFuse, a start-up medical device company focused on advanced surgical devices for improving outcomes for orthopaedic extremity procedures, announces that it has received FDA 510(k) clearance for its FlexThreadtm Fibula Pin System.

The IntraFuse FlexThreadtm Fibula Pin System provides percutaneous fixation of distal fibula fractures, primarily Danis-Weber B type fractures, or trans-syndesmotic fractures.  The simple and elegant design is easy to insert and cost competitive with today's standard-of-care internal fixation hardware. Incorporating IntraFuse's proprietary FlexThreadtm technology, the distal end of the implant is a flexible, intramedullary screw and the proximal end is a rigid, high-strength intramedullary rod.  Upon insertion of the implant into the fibula, the rigid rod portion of the implant spans and supports the fracture and the flexible screw portion bends as needed to thread into the intramedullary canal.  With internal screw fixation on one side of the fracture and cross screw fixation through the rod on the other side of the fracture, proper bone alignment and length can be maintained during the healing period. Additionally, the FlexThreadtm Fibula Pin is compatible with either screw or flexible fixation of the syndesmosis joint as needed.

To accommodate the anatomic size range of fibulas, the FlexThreadtm Fibula Pin is available in three different screw diameters, each with two length options.  Using routine intramedullary and screw fixation techniques, bone preparation is a simple, three step sequence:  place guide wire, ream, tap.   Optional fracture site compression is achieved concurrent with insertion of the implant, and delivery of cross fixation screws is facilitated by a guide that connects directly to the implant inserter.    

The FlexThreadtm Fibula Pin provides anatomic, intramedullary fixation that may have potential clinical advantages over fibula plating systems, including: reduced risk of hardware related pain, reduced rate of hardware removal, less risk of wound complications, infection and other morbidities due to a less invasive procedure, and less disruption of the periosteum which facilitates faster healing.

"Intramedullary fixation is the standard-of-care today for most fractures of the large, long bones of the body due to superior clinical outcomes versus plating systems, yet plating systems are still the standard-of-care for the smaller, long bones of the extremities," states Wade Fallin, CEO of IntraFuse.  Fallin continues, "FlexThreadtm is a platform technology that can address the unique requirements for intramedullary fixation of small bone fractures where off-axis entry into the bone canal is required, or where the bone is curved.  Now cleared for both clavicle and fibula fractures, the FlexThreadtm technology is in further development for additional indications."

IntraFuse is a development stage medical device company incubated and operated by Surgical Frontiers.  Inquiries regarding distribution and commercialization partnerships are welcome.

About Surgical Frontiers

Surgical Frontiers funds, launches and operates start-up companies to develop advanced surgical technologies that are ready for clinical use.   Focused primarily on musculoskeletal injuries and pathologies, the company collaborates with surgeons, industry, universities, and investors to bring advanced surgical technologies to the market that improve healthcare.  


Mr. Wade Fallin

SOURCE IntraFuse

These press releases may also interest you

at 00:31
ConnectedLife and Ocean Protocol announce their partnership to advance Parkinson's Disease diagnosis and treatment with safe sharing of patient-generated data. Photo - https://mma.prnewswire.com/media/838389/Trent_McConaghy_Founder.jpg By combining...

at 00:00
ICH GCP E6 R2 Meeting CRO-Vendor Oversight Requirements **An Interactive Workshop Presented by CenterWatch and Wool Consulting Group** March 27-28, 2019 Raleigh, NC...

at 00:00
Interstate Industries, Inc. d/b/a Hemi-Sync®, a leading conscious media company, has released a new title, Deep Connection: A Meditation for Two. Created and voiced by philosopher and best-selling author T!M FREKE, these meditations can transform...

at 00:00
The National Institute of Health estimated that Americans spend more than $36 billion on multivitamin supplements each year. But do the vitamins we take really contain the nutrients that are advertised? And how do we know for sure? That's why Jordi...

19 mar 2019
"We are thrilled with today's announcement by the federal government to support the creation of the Marathon of Hope Cancer Centres. Under this new Terry Fox Research Network, Canadian cancer centres, together with their research teams from coast to...

19 mar 2019
Physicians from several study sites involved in CalciMedica's initial acute pancreatitis clinical study of its CRAC channel inhibitor CM4620 (NCT03401109) and CalciMedica, Inc., presented a poster today at the 39th International Symposium on...

News published on 1 november 2017 at 08:45 and distributed by: